Business Description
The Oncology Institute Inc
NAICS : 621498
SIC : 8093
ISIN : US68236X1000
Total Employee Number:
641Compare
Compare
Traded in other countries / regions
TOI.USA Index Membership
Russell 2000Russell 3000Russell 3000Russell 2000 IPO Date
2021-11-15Description
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | -0.1 | |||||
Debt-to-Equity | -6.44 | |||||
Debt-to-EBITDA | -3.59 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.41 | |||||
Beneish M-Score | -2.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.2 | |||||
3-Year EPS without NRI Growth Rate | 24.7 | |||||
3-Year FCF Growth Rate | 28.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 28.97 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.86 | |||||
9-Day RSI | 67.24 | |||||
14-Day RSI | 65.63 | |||||
3-1 Month Momentum % | 51.24 | |||||
6-1 Month Momentum % | 19.66 | |||||
12-1 Month Momentum % | 90.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.47 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.38 | |||||
Days Inventory | 13.89 | |||||
Days Sales Outstanding | 37.69 | |||||
Days Payable | 30.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.5 | |||||
Shareholder Yield % | -0.05 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 15.12 | |||||
Operating Margin % | -5.99 | |||||
Net Margin % | -7.97 | |||||
EBITDA Margin % | -5.36 | |||||
FCF Margin % | -4.71 | |||||
OCF Margin % | -4 | |||||
ROA % | -26.52 | |||||
ROIC % | -36.58 | |||||
ROC (Joel Greenblatt) % | -71.22 | |||||
ROCE % | -37.5 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.03 | |||||
EV-to-EBIT | -17.76 | |||||
EV-to-EBITDA | -21.88 | |||||
EV-to-Revenue | 1.17 | |||||
EV-to-Forward-Revenue | 0.99 | |||||
EV-to-FCF | -24.86 | |||||
Price-to-GF-Value | 2.5 | |||||
Earnings Yield (Greenblatt) % | -5.63 | |||||
FCF Yield % | -4.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TOI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
The Oncology Institute Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 545.764 | ||
| EPS (TTM) ($) | -0.37 | ||
| Beta | -1.8281 | ||
| 3-Year Sharpe Ratio | 1 | ||
| 3-Year Sortino Ratio | 2.93 | ||
| Volatility % | 96.73 | ||
| 14-Day RSI | 65.63 | ||
| 14-Day ATR ($) | 0.357736 | ||
| 20-Day SMA ($) | 5.24 | ||
| 12-1 Month Momentum % | 90.23 | ||
| 52-Week Range ($) | 2.32 - 5.955 | ||
| Shares Outstanding (Mil) | 99.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
The Oncology Institute Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
The Oncology Institute Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 17:00 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 17:00 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 36 days | ||
| General meeting for 2026 | 2026-06-10 09:00 | 4.96 (-1.98%) | ||
| B. Riley Securities Institutional Investor Conference | 2026-05-21 21:00 | 4.20 (+2.19%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 17:30 | 3.80 (-4.52%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.80 (-4.52%) | ||
| 25th Annual Needham Healthcare Conference | 2026-04-15 15:45 | 3.38 (+1.81%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-12 17:00 | 2.76 (+5.34%) |
Show
Entries
The Oncology Institute Inc Frequently Asked Questions
What is The Oncology Institute Inc(TOI)'s stock price today?
The current price of TOI is $5.65. The 52 week high of TOI is $5.96 and 52 week low is $2.32.
When is next earnings date of The Oncology Institute Inc(TOI)?
The next earnings date of The Oncology Institute Inc(TOI) is 2026-08-13 Est..
Does The Oncology Institute Inc(TOI) pay dividends? If so, how much?
The Oncology Institute Inc(TOI) does not pay dividend.
Guru Commentaries on NAS:TOI
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| The Oncology Institute Announces a Strategic Partnership with IDEOlogy Health to Provide Customized Medical Education | 2023-05-04 |
Articles on The Oncology Institute Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers